These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36594243)

  • 1. Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy.
    Kalkan H; Pagano E; Paris D; Panza E; Cuozzo M; Moriello C; Piscitelli F; Abolghasemi A; Gazzerro E; Silvestri C; Capasso R; Motta A; Russo R; Di Marzo V; Iannotti FA
    EMBO Mol Med; 2023 Mar; 15(3):e16225. PubMed ID: 36594243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbes, metabolites and muscle: Is the gut-muscle axis a plausible therapeutic target in Duchenne muscular dystrophy?
    Marullo AL; O'Halloran KD
    Exp Physiol; 2023 Sep; 108(9):1132-1143. PubMed ID: 37269541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
    Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin-deficient mice.
    Farini A; Tripodi L; Villa C; Strati F; Facoetti A; Baselli G; Troisi J; Landolfi A; Lonati C; Molinaro D; Wintzinger M; Gatti S; Cassani B; Caprioli F; Facciotti F; Quattrocelli M; Torrente Y
    EMBO Mol Med; 2023 Mar; 15(3):e16244. PubMed ID: 36533294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy.
    Dubinin MV; Talanov EY; Tenkov KS; Starinets VS; Belosludtseva NV; Belosludtsev KN
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy.
    Iannotti FA; Pagano E; Guardiola O; Adinolfi S; Saccone V; Consalvi S; Piscitelli F; Gazzerro E; Busetto G; Carrella D; Capasso R; Puri PL; Minchiotti G; Di Marzo V
    Nat Commun; 2018 Sep; 9(1):3950. PubMed ID: 30262909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.
    Krishnan SM; Nordlohne J; Dietz L; Vakalopoulos A; Haning P; Hartmann E; Seifert R; Hüser J; Mathar I; Sandner P
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
    Iannotti FA; Pagano E; Moriello AS; Alvino FG; Sorrentino NC; D'Orsi L; Gazzerro E; Capasso R; De Leonibus E; De Petrocellis L; Di Marzo V
    Br J Pharmacol; 2019 May; 176(10):1568-1584. PubMed ID: 30074247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
    Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
    Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy.
    Dubuisson N; Davis-López de Carrizosa MA; Versele R; Selvais CM; Noel L; Van den Bergh PYD; Brichard SM; Abou-Samra M
    Front Immunol; 2022; 13():1049076. PubMed ID: 36569900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy.
    Luan P; D'Amico D; Andreux PA; Laurila PP; Wohlwend M; Li H; Imamura de Lima T; Place N; Rinsch C; Zanou N; Auwerx J
    Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy.
    Laurila PP; Luan P; Wohlwend M; Zanou N; Crisol B; Imamura de Lima T; Goeminne LJE; Gallart-Ayala H; Shong M; Ivanisevic J; Place N; Auwerx J
    Sci Adv; 2022 Jan; 8(4):eabh4423. PubMed ID: 35089797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
    Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
    Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
    Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.